Pterygium Clinical Trial
Official title:
A Novel Technique for the Removal of Pterygiums
Verified date | December 2014 |
Source | The University of The West Indies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to introduce a new surgical technique for the removal of pterygiums
that entails the use of bipolar electrocautery to secure the graft, rather than sutures.
With this, the objective is to evaluate the benefits of a new technique for pterygium surgery
with respect to postoperative patient comfort, surgery time, cost and recurrence rate.
Status | Unknown status |
Enrollment | 50 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with one or more pterygiums over age 18 Exclusion Criteria: - Patients with glaucoma |
Country | Name | City | State |
---|---|---|---|
Barbados | Queen Elizabeth Hospital | Bridgetown |
Lead Sponsor | Collaborator |
---|---|
The University of The West Indies |
Barbados,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Operating Cost | Cost Benefit Analysis. Total cost of pterygium surgery using sutures for graft attachment versus cost using cautery for graft attachment will be calculated and compared. | day 1 | |
Other | Recurrence | Any regrowth of the pterygium onto the cornea will be considered a recurrence | 1 year | |
Primary | Patient Discomfort | Grading of patients' symptoms (pain, foreign body sensation, irritation, and epiphora) will be done using a 5-point scale. The scale ranges from 0 to 4: 0 = no symptom at all; = presence of the symptom but easily tolerated; = presence of the symptom causing some discomfort; = presence of the symptom causing discomfort that interferes with usual activity or sleep; = presence of the symptom that completely interferes with usual activity or sleep. |
Day 1 | |
Primary | Patient Discomfort | Grading of patients' symptoms (pain, foreign body sensation, irritation, and epiphora) will be done using a 5-point scale. The scale ranges from 0 to 4: 0 = no symptom at all; = presence of the symptom but easily tolerated; = presence of the symptom causing some discomfort; = presence of the symptom causing discomfort that interferes with usual activity or sleep; = presence of the symptom that completely interferes with usual activity or sleep. |
Week 1 | |
Primary | Patient Discomfort | Grading of patients' symptoms (pain, foreign body sensation, irritation, and epiphora) will be done using a 5-point scale. The scale ranges from 0 to 4: 0 = no symptom at all; = presence of the symptom but easily tolerated; = presence of the symptom causing some discomfort; = presence of the symptom causing discomfort that interferes with usual activity or sleep; = presence of the symptom that completely interferes with usual activity or sleep. |
Week 2 | |
Primary | Patient Discomfort | Grading of patients' symptoms (pain, foreign body sensation, irritation, and epiphora) will be done using a 5-point scale. The scale ranges from 0 to 4: 0 = no symptom at all; = presence of the symptom but easily tolerated; = presence of the symptom causing some discomfort; = presence of the symptom causing discomfort that interferes with usual activity or sleep; = presence of the symptom that completely interferes with usual activity or sleep. |
Week 3 | |
Primary | Patient Discomfort | Grading of patients' symptoms (pain, foreign body sensation, irritation, and epiphora) will be done using a 5-point scale. The scale ranges from 0 to 4: 0 = no symptom at all; = presence of the symptom but easily tolerated; = presence of the symptom causing some discomfort; = presence of the symptom causing discomfort that interferes with usual activity or sleep; = presence of the symptom that completely interferes with usual activity or sleep. |
Week 7 | |
Primary | Patient Discomfort | Grading of patients' symptoms (pain, foreign body sensation, irritation, and epiphora) will be done using a 5-point scale. The scale ranges from 0 to 4: 0 = no symptom at all; = presence of the symptom but easily tolerated; = presence of the symptom causing some discomfort; = presence of the symptom causing discomfort that interferes with usual activity or sleep; = presence of the symptom that completely interferes with usual activity or sleep. |
3 months | |
Secondary | Operating time | Analysis. start time of operation, start time of conjunctival graft attachment and end time of operation will be recorded. | day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02641132 -
Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.
|
Phase 4 | |
Completed |
NCT02342392 -
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT01387971 -
Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders
|
N/A | |
Recruiting |
NCT05978687 -
The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision
|
Phase 4 | |
Not yet recruiting |
NCT06042296 -
Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
|
||
Completed |
NCT04022811 -
Effect of Bromfenac on Pain Related to Pterygium Surgery
|
Phase 4 | |
Recruiting |
NCT01249235 -
Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery
|
N/A | |
Recruiting |
NCT01261455 -
Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia
|
N/A | |
Completed |
NCT01115517 -
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
|
Phase 2 | |
Completed |
NCT00768963 -
Ranibizumab for the Inhibition of Neovascularization in Pterygia
|
Phase 1 | |
Completed |
NCT00949728 -
Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia
|
N/A | |
Recruiting |
NCT00563277 -
Surgical Treatment of Concurrent Cataract and Primary Pterygium
|
N/A | |
Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
Completed |
NCT03533244 -
A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
|
Phase 2 | |
Completed |
NCT04403516 -
Dextenza in Pterygium Surgery
|
Phase 4 | |
Recruiting |
NCT02911532 -
Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia
|
N/A | |
Not yet recruiting |
NCT03304366 -
Corneal Changes With Pentacam Before and After Pterygium
|
N/A | |
Unknown status |
NCT02015000 -
Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation
|
N/A | |
Completed |
NCT00344201 -
Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery
|
Phase 1 | |
Recruiting |
NCT00326560 -
Comparison of Glue With Sutures for Pterygium Surgery
|
Phase 3 |